Renaissance Capital logo

CytoMed Therapeutics Priced, Nasdaq: GDTC

Singaporean preclinical biotech developing gamma-delta T cell therapies for cancer.

Industry: Health Care

Latest Trade: $2.24 +0.04 (+1.8%)

First Day Return: 0.0%

Return from IPO: -45.0%

Industry: Health Care

We are a pre-clinical biopharmaceutical company focused on harnessing our proprietary technologies into creating novel cell-based immunotherapies for treatment of human cancers. The development of our novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. We believe that the current development of CD19-targeting CAR-T cells in treating B-cell malignancies signifies that cellular immunotherapy is becoming one of the pillars in cancer care. Built on the proprietary platform technologies that we licensed, we are developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is our lead product candidate and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity.
more less
IPO Data
IPO File Date 11/18/2022
Offer Price $4.00
Price Range $4.00 - $5.00
Offer Shares (mm) 2.4
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/13/2023
Offer Price $4.00
Price Range $4.00 - $5.00
Offer Shares (mm) 2.4
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
The Benchmark Company
Axiom Capital Management
Company Data
Headquarters Singapore
Founded 2018
Employees 25
Website www.cytomed.sg

CytoMed Therapeutics (GDTC) Performance